Skip to main content

RSV Information for Healthcare

RSV: Resources for Health Professionals

RSV usually causes mild symptoms, but it can cause severe illness. This is more likely in infants, some young children, people with compromised immune systems and adults who are older or have certain risk factors.

Healthcare providers should consider RSV in the differential diagnosis of patients with respiratory illness, particularly during the RSV season.

To protect infants and some young children, CDC recommends the maternal RSV vaccine (Pfizer’s Abrysvo) for pregnant women during weeks 32–36 of pregnancy, or a long-acting infant RSV antibody (nirsevimab or clesrovimab) for babies given after birth. Nirsevimab is recommended for some young children ages 8–19 months.

CDC also recommends a single dose of RSV vaccine to protect all adults ages 75 and older and adults ages 50–74 who are at increased risk of severe RSV.